HYPERIMAGE

Hybrid PET-MR system for concurrent ultra-sensitive imaging

Coordinatore	PHILIPS TECHNOLOGIE GMBH    more  Organization address address: LUEBECKERTORDAM 5 city: HAMBURG postcode: 20099 contact info Titolo: Mr. Nome: Patrick Cognome: Keur Email: send email Telefono: +31 402740361 Fax: +31 402745829
Nazionalità Coordinatore	Germany [DE]
Sito del progetto	http://www.iminds.be
Totale costo	7˙333˙956 €
EC contributo	4˙940˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-04-01   -   2011-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	PHILIPS TECHNOLOGIE GMBH  Organization address address: LUEBECKERTORDAM 5 city: HAMBURG postcode: 20099 contact info Titolo: Mr. Nome: Patrick Cognome: Keur Email: send email Telefono: +31 402740361 Fax: +31 402745829	DE (HAMBURG)	coordinator	0.00
2	FONDAZIONE BRUNO KESSLER  Organization address address: VIA SANTA CROCE 77 city: TRENTO postcode: 38122 contact info Titolo: Mr. Nome: Umberto Cognome: Silvestri Email: send email Telefono: +39 0461 314375 Fax: +39 0461 314588	IT (TRENTO)	participant	0.00
3	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III  Organization address address: C/ MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 contact info Titolo: Dr. Nome: Julia Cognome: Redondo Email: send email Telefono: +34 91 453 12 30 Fax: +34 91 453 12 45	ES (MADRID)	participant	0.00
4	IMINDS VZW  Organization address address: GASTON CROMMENLAAN 8/102 city: GENT postcode: 9050 contact info Titolo: Dr. Nome: Steven Cognome: Staelens Email: send email Telefono: +32 9 332 21 47 Fax: +32 9 332 41 59	BE (GENT)	participant	0.00
5	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 20 7848 8184 Fax: +44 20 7848 8187	UK (LONDON)	participant	0.00
6	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG  Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 contact info Titolo: Dr. Nome: Norbert Cognome: Huber Email: send email Telefono: 496222000000 Fax: 496222000000	DE (HEIDELBERG)	participant	0.00
7	STICHTING HET NEDERLANDS KANKER INSTITUUT  Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX contact info Titolo: Dr. Nome: Henri Cognome: Van Luenen Email: send email Telefono: 31205122097 Fax: 31206691383	NL (AMSTERDAM)	participant	0.00
8	UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF  Organization address address: Martinistrasse 52 city: HAMBURG postcode: 20246 contact info Titolo: Mr. Nome: Michael Cognome: Kaul Email: send email Telefono: 4940430000000 Fax: 4940430000000	DE (HAMBURG)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The HYPERImage project will develop a novel hybrid system for simultaneous whole-body PET/MR imaging for humans. It will advance the required Time-of-Flight (ToF) PET technology, and the software for MR mediated compensation of motion artefacts. The hybrid system will be validated in pre-clinical and initial clinical studies, for exemplary applications in cardiovascular diseases, and in breast cancer as one of the most relevant applications in oncology. For latter application, the concept will be extended from pure imaging towards image-guided therapy. Positron Emission Tomography (PET) is the most sensitive molecular imaging modality. Hybrid PET/CT systems using Computer Tomography (CT) to provide the anatomical reference for lesion localization have evolved to be the best choice for a number of applications in cardiology and oncology. However, PET/CT has drawbacks and limitations: CT is associated with radiation dose and lacks soft tissue contrast, and PET suffers from restrictions in small lesion detectability, both due to motion artefacts during the scan, and due to detector limitations. A hybrid combination of ToF-PET with a 3T MR has the potential to overcome these shortcomings, by fully exploiting the superior soft-tissue contrast of MR in combination with a new MR-compatible solid-state PET detector technology, and a sophisticated motion compensation enabled by concurrent acquisition of both MR and time-stamped PET data. In addition, the versatility of MR allows imaging of supplementary functional parameters like temperature, elasticity, and diffusion, enabling this new hybrid imaging concept to open up new fields of applications in therapy guidance and therapy response monitoring. The consortium consists of one large company, one SME, three academic partners and two research institutes from five different EU countries. It combines leadership in technology with pioneer experience in using biomedical imaging for diagnosis and therapy monitoring.'